Compare JILL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | CRBU |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7M | 179.7M |
| IPO Year | 2017 | 2021 |
| Metric | JILL | CRBU |
|---|---|---|
| Price | $12.80 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.00 | $10.75 |
| AVG Volume (30 Days) | 130.7K | ★ 1.4M |
| Earning Date | 06-10-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $596,549,000.00 | N/A |
| Revenue This Year | $2.65 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $7.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.41 | $0.73 |
| 52 Week High | $18.80 | $3.53 |
| Indicator | JILL | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 52.30 |
| Support Level | $10.41 | $1.70 |
| Resistance Level | $16.89 | $2.26 |
| Average True Range (ATR) | 0.61 | 0.12 |
| MACD | 0.24 | -0.01 |
| Stochastic Oscillator | 72.73 | 40.63 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.